stockrow
Friday 6 November 2026
Export NVCR’s income statement to Excel — free account
NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +72.9%
- Free cash flow
- +5.54%
- Total debt
- +0.87%
Quarter to September 2026, against a year earlier
13.26
0.29
−2.14%
Follow NVCR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.57 | 2.51 | 1.84 | 2.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
82.18 | 216.13 | (92.05) | (80.06) | |
P/B ratio |
5.31 | 5.20 | 3.76 | 4.23 | |
Price to Tangible BV |
5.31 | 5.20 | 3.76 | 4.23 | |
EV/Sales |
2.19 | 2.15 | 1.54 | 1.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2,195.95) | (533.92) | (38.59) | (24.04) | |
EV/FCF |
(64.43) | (59.09) | (21.58) | (15.58) | |
Quick Ratio |
2.34 | 2.70 | 2.70 | 2.71 | |
Current Ratio |
2.49 | 2.89 | 2.90 | 2.90 | |
Net Debt/EBITDA |
63.53 | 28.77 | 3.14 | 6.57 | |
Debt/Assets |
23.69% | 24.63% | 29.82% | 24.25% | |
Debt/Equity |
0.56 | 0.58 | 0.71 | 0.57 | |
Asset Turnover |
0.66 | 0.69 | 0.66 | 0.64 | |
Operating CF/Net income |
(2.17) | (0.52) | 0.19 | 0.73 | |
Capex/Depreciation |
(3.83) | (4.03) | (3.42) | (10.37) | |
Interest Coverage |
(3.61) | (5.59) | (36.68) | (72.00) | |
Research and Development Expense of Revenue |
30.04% | 28.02% | 33.52% | 34.93% | |
Selling, General and Administrative Expense of Revenue |
50.13% | 55.34% | 82.85% | 64.06% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9.04% | 9.27% | 36.20% | 11.37% | |
Graham Net Nets |
0.10 | 0.10 | 0.14 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.64%) | (8.58%) | (14.04%) | (9.44%) | |
Free Cash Flow Yield |
(1.32%) | (1.45%) | (3.86%) | (5.25%) | |
Revenue per Share |
1.66 | 1.58 | 1.52 | 1.56 | |
Operating CF per Share |
0.19 | 0.07 | (0.12) | (0.16) | |
Capex per Share |
(0.06) | (0.06) | (0.05) | (0.04) | |
Free Cash Flow per Share |
0.13 | 0.01 | (0.16) | (0.21) | |
Cash per Share |
4.06 | 3.88 | 3.87 | 4.10 | |
Shareholders Equity per Share |
3.00 | 2.91 | 2.90 | 3.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.00 | 2.91 | 2.90 | 3.05 | |
Free Cash Flow |
15.75 | 1.22 | (18.67) | (22.90) | |
Working Capital |
402.86 | 417.81 | 414.09 | 423.50 | |
Capital Expenditures |
(6.92) | (6.92) | (5.15) | (4.90) | |
Net Current Asset Value |
195.42 | 181.42 | 174.45 | 182.87 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
142.03 | 137.44 | 132.48 | 128.70 | |
Average Payables |
132.42 | 117.20 | 111.16 | 113.66 | |
Average Inventory |
39.85 | 41.22 | 41.46 | 38.10 | |
Average Assets |
1,094.95 | 1,020.53 | 1,018.37 | 1,022.56 | |
Average Common Equity |
345.97 | 343.77 | 346.34 | 350.32 |
Columns are period end dates · fundamentals updated 2 Nov 2026